TYSABRI conc perf 300 mg/15ml fl 15 ml
7680572730012
CH-57273
L04AG03
01.99.0.
Reimbursement limitations:
TYSABRI4
Au moment de la pose de l'indication ou avant le traitement, le risque de LEMP …
1 / 3
google
Details
- Product number
- 5727301
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- natalizumabum 300 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml corresp. natrium 52 mg.
Articles (1)
Tysabri 300 mg, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
300.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
52.0 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 1671.50
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/06/2007
Authorization holder
Biogen Switzerland AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 57273
- Drug name
- Tysabri 300 mg, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L04AG03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 03/05/2007
- Authorization expiration date
- 31/12/9999
- IT number
- 01.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- TYSABRI conc perf 300 mg/15ml fl 15 ml
- Description (DE)
- TYSABRI Inf Konz 300 mg/15ml Fl 15 ml
- Market launch
- 03/05/2007
- Narcotic (BTM)
- No